Image Credit: Medical Product Outsourcing
The stereotaxis, a leader headed company in surgical robotics for less invasive endovascular intervention and cardiofocus, Inc., a leading medical device company committed to advancing ablation treatment for the condition of cardiac arrhythmias, have confirmed their collaboration agreement. The purpose of this partnership is to bring specific advancement and improvement into the robotic pulsed field ablation (PFA) technology for better commercialisation.
The partnership merges the exclusive technologies from both companies to leverage the marketising value and access of the first invented robotic PFA solution for the cure of cardiac arrhythmias. The cardiofocus’s centauri pulsed field ablation (PFA) system is a future-discovered PFA system. The Centauri system is CE-certified and suitable, as it is used to cure above 9,000 patients throughout Europe. Following the clinical experience registered in over 40 publications, elaborating a superior level of durable cardiac lesions, lower rates of complications and procedural efficiency.
Whereas, stereotaxis’ robotic magnetic navigation (RMN) systems show the safety and accuracy of advanced robotic technology in cardiac ablation procedures inclined with clinical value specified in above 150,000 cardiac ablation patients cured globally, along with 500 publications.
The Stereotaxis and CardioFocus have come together to couple the Centauri PFA system with Stereotaxis’ robust MAGiC robotic cardiac ablation catheter. The companies have progressively accomplished the preclinical testing and extensive bench of the Centauri with MAGiC. Involving current crucial preclinical studies that elaborated convincing lesions, safe and efficient delivery consisting of the ocean deep durable lesions presence in ventricular tissue. The collaboration agreement has stepped in in the company's favour to advance this joint solution for a clinical trial. Further, offering commercial accessibility and regulatory compatibility of Centauri and MAGiC.
The Stereotaxis chairman and CEO, David Fischel, said, “We are thrilled to partner with cardiofocus to leverage the presence of the robotic PFA in the electrophysiology space. The balance, safety and accurate profile of robotics, along with the impressive and efficient lesions generated by Centauri, is a winning level merge. We’re looking forward to transforming into the first human use and improving the regulatory process soon.”
The CEO of cardiofocus, Stephan Ogilvie, said, “The merger of our marked PFA waveform and the excellent MAGiC catheter can advance patient lives. With the strict scientific development, we have customised our evident PFA waveform especially for stereotaxis’ RMN systems and expect the partnership to improve patient care in electrophysiology.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
